CITIC Securities Maintains "Buy" Rating on GIANT BIOGENE (02367) with HK$44 Target Price

Stock News12-11

CITIC Securities stated in a research report that GIANT BIOGENE (02367) faced sales pressure during the Double 11 shopping festival due to industry headwinds and operational decisions, prompting a downward revision of its 2025 revenue and profit forecasts. However, the company retains solid brand assets and demonstrates structural strengths in operations.

Looking ahead, the firm has clear short- and long-term strategies. Its brand "Kefumei" has set a revenue target of RMB 10 billion with a detailed roadmap covering product development, operations, and channels. Meanwhile, "Kerlijin" is undergoing a brand revamp alongside new product launches, with potential to become the next OTC blockbuster brand.

CITIC adjusted its 2025 revenue and net profit forecasts to RMB 5.49 billion and RMB 1.93 billion, respectively, while revising adjusted net profit attributable to shareholders to RMB 1.98 billion. Based on a 20x 2026 P/E multiple, the target price is set at HK$44, maintaining a "Buy" rating.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1129102228?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 10:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129102228","market":"fut","top_or_hot":-1,"title":"CITIC Securities Maintains \"Buy\" Rating on GIANT BIOGENE (02367) with HK$44 Target Price","media":"Stock News","content":"<p>CITIC Securities stated in a research report that GIANT BIOGENE (02367) faced sales pressure during the Double 11 shopping festival due to industry headwinds and operational decisions, prompting a downward revision of its 2025 revenue and profit forecasts. However, the company retains solid brand assets and demonstrates structural strengths in operations.</p>\n<p>Looking ahead, the firm has clear short- and long-term strategies. Its brand \"Kefumei\" has set a revenue target of RMB 10 billion with a detailed roadmap covering product development, operations, and channels. Meanwhile, \"Kerlijin\" is undergoing a brand revamp alongside new product launches, with potential to become the next OTC blockbuster brand.</p>\n<p>CITIC adjusted its 2025 revenue and net profit forecasts to RMB 5.49 billion and RMB 1.93 billion, respectively, while revising adjusted net profit attributable to shareholders to RMB 1.98 billion. Based on a 20x 2026 P/E multiple, the target price is set at HK$44, maintaining a \"Buy\" rating.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CITIC Securities Maintains \"Buy\" Rating on GIANT BIOGENE (02367) with HK$44 Target Price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCITIC Securities Maintains \"Buy\" Rating on GIANT BIOGENE (02367) with HK$44 Target Price\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-11 10:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CITIC Securities stated in a research report that GIANT BIOGENE (02367) faced sales pressure during the Double 11 shopping festival due to industry headwinds and operational decisions, prompting a downward revision of its 2025 revenue and profit forecasts. However, the company retains solid brand assets and demonstrates structural strengths in operations.</p>\n<p>Looking ahead, the firm has clear short- and long-term strategies. Its brand \"Kefumei\" has set a revenue target of RMB 10 billion with a detailed roadmap covering product development, operations, and channels. Meanwhile, \"Kerlijin\" is undergoing a brand revamp alongside new product launches, with potential to become the next OTC blockbuster brand.</p>\n<p>CITIC adjusted its 2025 revenue and net profit forecasts to RMB 5.49 billion and RMB 1.93 billion, respectively, while revising adjusted net profit attributable to shareholders to RMB 1.98 billion. Based on a 20x 2026 P/E multiple, the target price is set at HK$44, maintaining a \"Buy\" rating.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999004311.SGD","symbol_name":"Nikko AM Shenton Emerging Enterprise Discovery Fund SGD","start_time":0,"source_url":"","article_id":"1129102228","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129102228","pubTimestamp":1765420388,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CITIC Securities stated in a research report that GIANT BIOGENE (02367) faced sales pressure during the Double 11 shopping festival due to industry headwinds and operational decisions, prompting a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999004311.SGD":"Nikko AM Shenton Emerging Enterprise Discovery Fund SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","02367":"巨子生物","BK1207":"个人用品"},"translate_title":"中信证券维持巨人生物基因(02367)“买入”评级目标价44港元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02367":1},"content_text":"CITIC Securities stated in a research report that GIANT BIOGENE (02367) faced sales pressure during the Double 11 shopping festival due to industry headwinds and operational decisions, prompting a downward revision of its 2025 revenue and profit forecasts. However, the company retains solid brand assets and demonstrates structural strengths in operations.\nLooking ahead, the firm has clear short- and long-term strategies. Its brand \"Kefumei\" has set a revenue target of RMB 10 billion with a detailed roadmap covering product development, operations, and channels. Meanwhile, \"Kerlijin\" is undergoing a brand revamp alongside new product launches, with potential to become the next OTC blockbuster brand.\nCITIC adjusted its 2025 revenue and net profit forecasts to RMB 5.49 billion and RMB 1.93 billion, respectively, while revising adjusted net profit attributable to shareholders to RMB 1.98 billion. Based on a 20x 2026 P/E multiple, the target price is set at HK$44, maintaining a \"Buy\" rating.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1129102228","isCrawlerRequest":true}